Global Narcolepsy Treatment market to Grow at 5.1% CAGR ... Usage: Approved for improving wakefulness in adults with EDS due to narcolepsy or obstructive sleep apnea. Market Position: Expected ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy ... to include the treatment of epilepsy in adults.

and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets ...

The CDC recommends 7 or more hours of nightly sleep for adults ... its treatments may be helpful. For more pervasive anxiety, seeing a therapist or psychologist may be helpful. Since narcolepsy ...

and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets ...

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category ... extend Buccolam's indication to include the treatment of epilepsy ...

Detailed price information for Nasdaq Biotechnology Ishares ETF (IBB-Q) from The Globe and Mail including charting and trades.